Literature DB >> 16641790

Imaging of malignant liver masses: characterization and detection.

Hyun-Jung Jang1, Tae Kyoung Kim, Stephanie R Wilson.   

Abstract

Noninvasive characterization of focal liver lesions is largely based on their enhancement patterns on contrast-enhanced imaging. The use of microbubble contrast agents combined with specialized ultrasound (US) techniques has significantly expanded the role of US in the diagnosis of focal liver lesions based on their vascularity and specific enhancement features. With the advantage of real-time scanning, contrast-enhanced ultrasound (CEUS) can evaluate small lesions that are indeterminate on computed tomography (CT) or magnetic resonance imaging (MR), because CEUS is far less affected by timing issues. Hepatocellular carcinoma is typically characterized by increased arterial flow with frequent dysmorphic tumor vessels and decreased portal venous flow. However, negative enhancement in the portal phase is often not obvious until late (>2 minutes). On the other hand, metastasis shows prompt brief arterial hypervascularity, with either a rim or diffuse pattern and rapid washout, seen as perfusion defects during the portal venous phase. This pattern of complete rapid washout of metastases within the homogeneously enhanced background liver parenchyma can improve their detection and also improve differentiation from hepatocellular carcinoma or benign focal lesions. All malignant lesions generally show negative enhancement or washout during the extended portal venous phase, and this pattern is useful to differentiate them from benign lesions. Microbubble agents, confined to the intravascular space, may infrequently characterize malignancy by showing washout whereas CT or MR shows persistent enhancement due to interstitial distribution.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16641790

Source DB:  PubMed          Journal:  Ultrasound Q        ISSN: 0894-8771            Impact factor:   1.657


  8 in total

1.  Multiple anechoic hepatic nodules in a patient with malignant lymphoma: report of a case with an emphasis on B-mode sonograms.

Authors:  Yoko Ohyama; Junko Konno; Chioko Yoshida; Naoko Kudoh; Toshiki Sasaki; Takao Hoshino; Hiroyuki Watanabe; Hideaki Ishida; Kayoko Furukawa; Takako Watanabe
Journal:  J Med Ultrason (2001)       Date:  2008-12-16       Impact factor: 1.314

2.  Role of contrast enhanced ultrasonography in the assessment of hepatic metastases: A review.

Authors:  Lars Peter Skovgaard Larsen
Journal:  World J Hepatol       Date:  2010-01-27

Review 3.  Use of second generation contrast-enhanced ultrasound in the assessment of focal liver lesions.

Authors:  Stanislas-H Morin; Adrian-Kp Lim; Jeremy-Fl Cobbold; Simon D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

4.  Contrast-enhanced ultrasound in planning thermal ablation of liver metastases: Should the hypervascular halo be included in the ablation volume?().

Authors:  A Andreano; E Meneghel; G Bovo; D Ippolito; A Salvioni; C Filice; S Sironi; M F Meloni
Journal:  J Ultrasound       Date:  2010-11-18

Review 5.  Contrast-enhanced ultrasound in the diagnosis of nodules in liver cirrhosis.

Authors:  Tae Kyoung Kim; Hyun-Jung Jang
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

Review 6.  Synchronous double primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma: A case report and review of the literature.

Authors:  Meng-Meng Qu; Yuan-Hui Zhu; Yi-Xiang Li; Zhi-Fan Li; Jin-Kui Li; Yong-Sheng Xu; Manishkumar Shrestha; Jun-Qiang Lei
Journal:  Medicine (Baltimore)       Date:  2021-11-19       Impact factor: 1.889

Review 7.  Contrast-enhanced ultrasound in the detection and characterization of liver tumors.

Authors:  Hyun-Jung Jang; Hojun Yu; Tae Kyoung Kim
Journal:  Cancer Imaging       Date:  2009-11-06       Impact factor: 3.909

8.  Liver Imaging Techniques: Recognition of Uveal Melanoma Metastases.

Authors:  Claudine Bellerive; Etienne Ouellet; Aya Kamaya; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2018-01-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.